Risultati di ricerca
Dr. Plotkin continued to work on vaccines throughout his professional career. He was on the team that developed a human rabies vaccine at the Wistar Institute (licensed in 1980). He also consulted for different vaccine manufacturers in his “retirement.”. During the COVID-19 pandemic, Dr. Plotkin was sought for advice on the recommendations ...
4 apr 2018 · Stanley Plotkin (SP): So, I have already published one article answering that question in The Pediatric Infectious Disease Journal, years ago. It was titled, if I recall correctly, ‘The late sequelae of Arrowsmith’. The reason for the title was that when I was 15, I read two books.
2 giorni fa · Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute, and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia.
Rubella Isolated, Epidemics of the 1960s, and Dr. Plotkin Begins Work on Vaccines. In the 1960s, the rubella virus was isolated in the laboratory. It was then that various laboratory teams began to develop a vaccine. One of those teams worked at the Wistar Institute in Philadelphia, and it included Dr. Stanley A. Plotkin.
Stanley Plotkin: The Bright Spark of Cytomegalovirus Vaccines. It is a tremendous pleasure and indeed honor for me to introduce Dr. Stanley Plotkin, a living legend in the world of vaccines, who will present a personal view of the current state of affairs in cytomegalovirus (CMV) vaccine development. Dr. Plotkin, more than any other individual ...
18 ago 2014 · Stanley Plotkin [email protected] Authors Info & Affiliations Edited by Rino Rappuoli, Novartis Vaccines, Siena, Italy, and approved February 5, 2014 (received for review January 13, 2014) August 18, 2014
Audio Interview from the New England Journal of Medicine — Interview with Dr. Stanley Plotkin on a strategy for stimulating and supporting global vaccine research.
